FDA Brief

Warning letters Drugs

FDA warning letter to

Aruba Aloe Balm N.V.

High riskIssued May 13, 2024Posted May 28, 2024Center for Drug Evaluation and Research | CDER

Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

What happened

FDA inspected the facility from November 13 to 16, 2023 and found significant CGMP violations. The firm used two ethanol lots containing about 4.75% methanol in hand sanitizer and Alcoholada Gel sent to the U.S., did not adequately test glycerin and propylene glycol for DEG/EG, did not monitor its water system microbiologically, and released OTC drugs without full identity, strength, or microbial testing. FDA also found the sunscreen Island Remedy All-Day Revitalizing Moisturizer label missing a required warning.

What FDA found

  1. The firm did not test incoming raw materials and active ingredients for identity, purity, strength, and quality, and used ethanol whose certificate said it was not intended for use as an active ingredient.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm used two ethanol lots containing about 4.75% methanol in hand sanitizers and Alcoholada Gel that were distributed to the United States.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The firm did not adequately test each lot of glycerin and propylene glycol, high-risk components, for diethylene glycol and ethylene glycol using the USP identity test.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. The firm did not show that its water system produced water suitable for use or adequately monitor the microbiological quality of the water.

  5. The firm released OTC drugs without full identity, strength, or microbiological testing, lacked adequate stability data, and did not adequately validate its manufacturing processes.

    21 CFR 211.165(a), 211.165(b), 211.166(a), 211.166(b), and 211.100(a)
  6. The Island Remedy All-Day Revitalizing Moisturizer sunscreen label omitted the required 'Do not use on damaged or broken skin' warning.

    FD&C Act section 502(f)(2), 21 U.S.C. 352(f)(2); M020.50(d)(1)(i)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with corrective actions, including a material system review, component and water testing plans, DEG and EG retain testing, risk assessments, and any needed customer notifications or recalls. FDA also recommends a qualified CGMP consultant and a six-system audit.

Who should pay attention

  • brands that buy OTC drugs or contract-manufactured products from this firm
  • U.S. retailers and distributors of hand sanitizers or Alcoholada Gel
  • companies sourcing glycerin or propylene glycol for drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk